Skip to content

OABI

OmniAb, Inc.

NASDAQ · USHealthcareBiotechnology
$2.08-1.89%

Price as of Jul 20, 2026

OABI growth

OmniAb, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
+8.1%
EBITDA
+27.9%
EBIT
+18.2%
EPS
+20.7%
Free cash flow
+34.4%
Operating cash flow
+33.8%

Forward estimates

Revenue
+3.0%
EBITDA
+44.8%
EPS
+6.5%

Three-year CAGR

Revenue
-31.9%
EBITDA
+6.9%
EBIT
+4.0%
Net income
-4.4%
EPS
+6.6%
Free cash flow
+10.9%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.